Marshall Wace’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Marshall Wace’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-34,292	Closed	-$3.44M	–	3552
2025 Q3	$3.44M	Buy	34,292 +30,269	+752%	+$2.73M	﹤0.01%	1354
2025 Q2	$334K	Sell	4,023 -20,971	-84%	-$1.67M	﹤0.01%	2295
2025 Q1	$2.03M	Buy	24,994 +17,071	+215%	+$1.53M	﹤0.01%	1461
2024 Q4	$714K	Buy	7,923 +2,600	+49%	+$252K	﹤0.01%	1887
2024 Q3	$526K	Sell	5,323 -10,767	-67%	-$1.06M	﹤0.01%	1907
2024 Q2	$1.49M	Buy	16,090 +13,290	+475%	+$1.19M	﹤0.01%	1504
2024 Q1	$266K	Sell	2,800 -2,700	-49%	-$251K	﹤0.01%	2156
2023 Q4	$491K	Sell	5,500 -3,719	-40%	-$276K	﹤0.01%	1719
2023 Q3	$673K	Sell	9,219 -110,671	-92%	-$8.84M	﹤0.01%	1629
2023 Q2	$9.97M	Buy	119,890 +19,770	+20%	+$1.65M	0.02%	728
2023 Q1	$7.63M	Buy	+100,120	New	+$8.31M	0.02%	809
2021 Q4	–	Sell	-34,960	Closed	-$4.22M	–	4332
2021 Q3	$4.39M	Buy	+34,960	New	+$4.5M	0.02%	1010
2021 Q2	–	Sell	-39,139	Closed	-$5.15M	–	3154
2021 Q1	$5.31M	Buy	+39,139	New	+$5.86M	0.02%	801
2019 Q4	–	Sell	-10,967	Closed	-$836K	–	2119
2019 Q3	$836K	Buy	+10,967	New	+$911K	0.01%	985
2018 Q4	–	Sell	-16,845	Closed	-$1.61M	–	1844
2018 Q3	$1.61M	Buy	+16,845	New	+$1.63M	0.01%	721
2018 Q2	–	Sell	-136,825	Closed	-$12M	–	856
2018 Q1	$12M	Sell	136,825 -79,098	-37%	-$7.22M	0.5%	59
2017 Q4	$18.3M	Buy	+215,923	New	+$18.1M	0.77%	31
2017 Q2	–	Sell	-79,271	Closed	-$5.47M	–	396
2017 Q1	$5.47M	Buy	+79,271	New	+$5.32M	0.26%	85

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Marshall Wace's XBI Position: Q4 2025 in Review

Marshall Wace sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2025, closing a stake of 34,292 shares — an estimated $3.44M sold.

Marshall Wace first reported a position in XBI in Q1 2017 and held it in 18 quarters. The position peaked at $18.3M in Q4 2017. 814 funds tracked by Wall St. Rank hold XBI as of Q4 2025.

Marshall Wace reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2025 after selling out during the quarter.
Marshall Wace sold 34,292 State Street SPDR S&P Biotech ETF shares in Q4 2025, an estimated $3.44M.
Marshall Wace first reported a position in State Street SPDR S&P Biotech ETF in Q1 2017 and held it in 18 quarters.
Marshall Wace's State Street SPDR S&P Biotech ETF position peaked at $18.3M in Q4 2017.
814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2025.

Based on Marshall Wace's 13F filing for Q4 2025, filed 13 Feb 2026.